COMPASS Pathways plc (CMPS)
| Market Cap | 295.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -137.80M |
| Shares Out | 93.56M |
| EPS (ttm) | -1.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,779,220 |
| Open | 2.840 |
| Previous Close | 2.800 |
| Day's Range | 2.820 - 3.239 |
| 52-Week Range | 2.250 - 8.537 |
| Beta | 2.15 |
| Analysts | Strong Buy |
| Price Target | 17.83 (+464.24%) |
| Earnings Date | Jul 31, 2025 |
About CMPS
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, th... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price target is $17.83, which is an increase of 464.24% from the latest price.
News
Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360
I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 d...
Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.
Compass Pathways stock slip as psilocybin depression trial falls short of expectations
Shares of Compass Pathways Plc plunged as much as 37% during pre-market trading on Monday after the company's experimental psilocybin treatment for a form of hard-to-treat depression produced results ...
Compass Pathways' depression drug succeeds late-stage trial
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod...
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical O...
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced toda...
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc...
This Is a Test From GlobeNewswire
This is a test from GlobeNewswire. Readers are advised to disregard.
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc...
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc...
Compass Pathways to Participate in Stifel Virtual CNS Forum
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways: Betting On The Future Of Psilocybin Therapy
Compass Pathways is positioned to leverage regulatory tailwinds and compelling clinical data, despite broader skepticism and high cash burn in the psychedelic biotech sector. The company has a financi...
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Stifel initiated coverage on Compass Pathways plc CMPS, saying, “The Time Is Now for Psychedelics.”
COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief ...
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental ...
Compass Pathways Announces Pricing of Underwritten Offering
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
LONDON--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announc...